Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 7/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 5/20 | 0.33 |
| ▸ | PPARD | Q03181 | 5/20 | 0.33 |
| ▸ | PPARA | Q07869 | 5/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | FABP4 | P15090 | 2/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.33 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23671685 | 0.95 | ALDH1A1 (0.50) | ALDH1A1CYP3A4FOLH1LMNASLC22A6 | |
| SCHEMBL30886725 | 0.82 | CA1 (0.35) | CYP3A4FOLH1 | |
| SCHEMBL29310328 | 0.82 | TSHR (0.47) | ALDH1A1CYP3A4LMNATSHRMEN1 | |
| SCHEMBL25213503 | 0.80 | TSHR (0.43) | ALDH1A1FOLH1LMNASLC22A6TSHR | |
| SCHEMBL5165664 | 0.79 | CYP3A4 (0.41) | ALDH1A1CYP3A4TSHRPPARDTDP1 | |
| SCHEMBL29310324 | 0.78 | DGKA (0.33) | ALDH1A1CYP3A4 | |
| SCHEMBL23671639 | 0.77 | TSHR (0.45) | ALDH1A1CYP3A4LMNATSHRPPARG | |
| SCHEMBL26696185 | 0.77 | TSHR (0.52) | ALDH1A1CYP3A4SLC22A6TSHRAKR1B1 | |
| SCHEMBL3817581 | 0.76 | CYP3A4 (0.67) | CYP3A4TSHR | |
| SCHEMBL2984826 | 0.76 | SMN1; SMN2 (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605393-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-08-27 | — | — | EP | disclosed |
| EP-4566608-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2025-06-05 | — | — | US | disclosed |
| CN-120077046-A | Triazole-substituted imidazo [1,2-A ] pyrimidines as CGAS inhibitors | 葛兰素史密斯克莱知识产权发展有限公司 | 2025-05-30 | — | — | CN | disclosed |
| EP-4440702-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| EP-4445900-B1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES INC (US) | 2025-05-21 | — | — | EP | disclosed |
| US-20250092053-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-20 | — | — | US | disclosed |
| US-12247033-B2 | Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-4445900-A2 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | Gilead Sciences, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| WO-2014011974-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-01-16 | — | — | WO | disclosed |
| US-20140018319-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-16 | — | — | US | disclosed |
| US-6846925-B2 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
| US-20040142909-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED | 2004-07-22 | — | — | US | disclosed |
| US-6720323-B2 | N-((5S)-3,9,10,11-TETRAMETHOXY-6,7-DIHYDRO-5H-DIBENZO(A,C) CYCLOHEPTEN-5-YL)-2-(2-AMINOACETYLAMINO)ACETAMIDE; DESTROYS NEWLY FORMED VASCULATURE WHILE LEAVING UNAFFECTED NORMAL, MATURE VASCULATURE. | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2004-04-13 | — | — | US | disclosed |
| US-20030195173-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| EP-1301498-A1 | COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS | Angiogene Pharmaceuticals Limited (GB) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002008213-A1 | COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
| EP-0468998-A1 | PEPTIDES HAVING NOVEL POLAR N-TERMINAL GROUPS | THE UPJOHN COMPANY (US) | 1992-02-05 | — | — | EP | disclosed |
| WO-1990012804-A2 | PEPTIDES HAVING NOVEL POLAR N-TERMINAL GROUPS | THE UPJOHN COMPANY (US) | 1990-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12247033-B2 | Triazole-substituted imidazo[1,2-a]pyrimidines as cGAS inhibitors | CGAS, SSB, STING1 | ALDH1A1 2358/4885CYP3A4 2151/4885FOLH1 2729/4885 |
| US-20250179102-A1 | THERAPEUTICS COMPOUNDS FOR HIV VIRUS INFECTION | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885CYP3A4 1335/4885FOLH1 911/4885 |
| US-20030195173-A1 | Colchinol derivatives as angiogenesis inhibitors | FLT1, CCNO, FLT4 | ALDH1A1 3893/4885CYP3A4 3192/4885FOLH1 1683/4885 |
| US-20140018319-A1 | IMIDAZOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | ABL1, MAP4K2, MAP3K1 | ALDH1A1 2258/4885CYP3A4 2078/4885FOLH1 3550/4885 |
| US-12187753-B2 | Therapeutics compounds for HIV virus infection | CD4, HAVCR2, MAVS | ALDH1A1 1512/4885CYP3A4 1335/4885FOLH1 911/4885 |
| US-20250092053-A1 | TRIAZOLE-SUBSTITUTED IMIDAZO[1,2-A]PYRIMIDINES AS CGAS INHIBITORS | CGAS, SSB, STING1 | ALDH1A1 2358/4885CYP3A4 2151/4885FOLH1 2729/4885 |
| US-20040142909-A1 | Colchinol derivatives as angiogenesis inhibitors | FLT1, CCNO, FLT4 | ALDH1A1 3911/4885CYP3A4 3207/4885FOLH1 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.